Courts and litigants continue to grapple with the new frontier of artificial intelligence (“AI”).  One recent case in California demonstrates a new wrinkle in this evolving landscape—the use of AI to aggregate class claims.

Because class settlements bind absent class members who do not object or opt out, Rule 23 requires courts to carefully review and approve them as “fair, reasonable, and adequate.”  An important part of this inquiry is making sure class members are given adequate notice of the terms of the proposed settlement and their rights.  When class members are required to submit claims to access settlement benefits, parties often turn to professional claims administration companies to assist in providing notice and facilitating the claims process.  Under Rule 23, courts closely monitor the information that flows from class counsel and claims administrators to putative class members to make sure it complies with due process.

ClaimClam—a company that uses AI to aggregate and submit class claims—adds a troubling wrinkle to this process.  ClaimClam leverages its members’ personal information and AI to identify proposed settlements in which members might be able to participate, and then submit claims on their behalf.  In doing so, ClaimClam provides information to putative class members without oversight from class counsel, the claims administrator, or the Court.  This gives rise to significant concerns about whether putative class members are getting full and accurate information, and thus whether they are making informed choices about participation. 

In a recent class action involving Juul, ClaimClam attempted to submit tens of thousands of class claims and opt-outs “en masse.”  The claims administrator rejected these en masse claims in part because ClaimClam provided incorrect or misleading information to potential class members.  ClaimClam and its CEO objected, but on September 19, Northern District of California Judge William Orrick overruled ClaimClam’s objections and granted final approval of the class settlement.  In re Juul Labs, Inc., Mktg., Sales Practices, and Prod. Liab. Litig., 2023 WL 6205473 (N.D. Cal. Sept. 19, 2023).  In doing so, the Court determined that the settlement administrator had properly disallowed the en masse claims, reasoning that “[a]llowing en masse submissions by claims aggregators like ClaimClam raises real risks that Class Members will not receive accurate information regarding the scope of the class and the claims process.”  Id. at *9.  Further, en masse submissions impact the ability of the claims administrator to communicate directly with class members to, for example, weed out fraudulent claims.  Id.  To protect ClaimClam’s customers, the Court provided a mechanism for the ClaimClam claimants to individually submit claims.   

Putting aside the notice concerns that motivated the decision in In re Juul, AI claims aggregation also gives rise to significant concerns regarding the accuracy and validity of claims that are submitted.  If AI-assisted claims are inaccurate, qualifying class members may have their benefits diluted by participation of non-qualifying individuals.  And for certain claims-made settlement structures, defendants may end up paying out more than they otherwise should. 

Recent experience in mass tort litigation—where mass filing of unexamined claims is routine—provides reason for concern.  The MDL Subcommittee of the Advisory Committee on Civil Rules remarked in 2018 that “a significant number of [MDL] claimants ultimately (often at the settlement stage) turn out to have unsupportable claims,” including because “the claimant did not use the product involved” or “had not suffered the adverse consequence in suit.”  The Advisory Committee estimated that the “proportion of claims falling into this category . . . may be as high as 40% or 50%.”  Id.  It remarked that one reason offered to explain this phenomenon is “the effect of ‘1-800’ lawyers and ‘claims generators’ who support an atmosphere of ‘get a name, make a claim’ . . . in the expectation that there will be a settlement in the MDL transferee court in which they can get ‘inventory value’ for their claims.”  Id. at 143.  The incentives are much the same for class action claims generators like ClaimClam, which charges claimants a “service fee” of at least fifteen percent of any recovery.  ClaimClam, Authorized Agent Agreement § 2, https://drive.google.com/file/d/1JdDvAXaBvHnDvjW4tawExtgPoLMnK9pS/view.

We continue to monitor the impact of AI across litigation and especially in the class actions space.  We will highlight future AI-related developments in the blog.  Covington’s cross-disciplinary teams are ready to assist clients on a broad range of AI issues.

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Marc Capuano Marc Capuano

Marc Capuano is a stand-up litigator in the Washington, DC office, where he represents clients in all phases of complex class actions and commercial litigation, including dispositive motions, discovery, and trial.

Marc works with national and international clients across various industries to help…

Marc Capuano is a stand-up litigator in the Washington, DC office, where he represents clients in all phases of complex class actions and commercial litigation, including dispositive motions, discovery, and trial.

Marc works with national and international clients across various industries to help them successfully resolve their most difficult litigation challenges in state and federal court. Among others, Marc has counseled clients in the life sciences, pharmaceutical, technology, and automotive industries. Marc has expertise in all stages of litigation, including drafting dispositive motions, taking and defending depositions, and in-court argument. A member of multiple trial teams in both state and federal court, Marc understands how to position and prepare cases for successful resolution at trial.

Marc’s active pro bono practice includes first-chairing a Maryland first degree murder trial during which the team secured their client’s acquittal and successful litigation to defend the rights of swing-state voters following the 2020 Presidential election. Marc has honed his oral advocacy through his pro bono work, including by arguing Daubert and other substantive motions, giving the opening statement at trial, and conducting trial cross and direct examinations.

Prior to joining Covington, Marc served as a law clerk to U.S. District Judge Robert E. Payne of the Eastern District of Virginia (Richmond). A native Rhode Islander, before attending law school, Marc worked as Correspondence Director and Legislative Correspondent for U.S. Senator Jack Reed (RI) in Washington.

Photo of Steve Petkis Steve Petkis

Steve Petkis is an associate in Covington’s Washington, DC office, where he represents a variety of clients in their most sensitive, complex, and high-stakes litigation matters in both state and federal court. He regularly defends life sciences clients and other regulated entities against…

Steve Petkis is an associate in Covington’s Washington, DC office, where he represents a variety of clients in their most sensitive, complex, and high-stakes litigation matters in both state and federal court. He regularly defends life sciences clients and other regulated entities against class action and mass tort claims that span jurisdictions.

Steve handles cases from pre-litigation planning through appeal, with a proven record of delivering victories at all stages. He was a member of the trial team that secured a complete defense win for McKesson in a landmark public nuisance case involving prescription opioid medications. In addition, his briefing strategies, fact and expert depositions, and courtroom stand-up have helped steer a number of other clients to highly-favorable resolutions that eliminate billions of dollars in potential exposure.

Steve previously served as a law clerk to Judge Katherine B. Forrest on the United States District Court for the Southern District of New York. He maintains an active pro bono practice focused on civil rights and criminal justice issues.

Photo of Gregory Halperin Gregory Halperin

Greg Halperin is a trial lawyer with experience spanning more than 170 trial days. He has particular expertise representing clients in the life sciences industry in complex product liability and mass tort litigation.

As a member of eight trial teams, Greg has experience…

Greg Halperin is a trial lawyer with experience spanning more than 170 trial days. He has particular expertise representing clients in the life sciences industry in complex product liability and mass tort litigation.

As a member of eight trial teams, Greg has experience crafting opening statements and closing arguments, and examining key fact and expert witnesses at trial. Greg was a member of the team that tried the first opioids case involving wholesale distributors to verdict, resulting in a complete defense win. He also participated in trial wins involving Pradaxa and Roundup.

Greg is skilled in all stages of litigation, including taking and defending depositions, preparing witnesses, and drafting Daubert and dispositive motions. He has argued numerous motions in state and federal court, including recently in the first multi-plaintiff trial in St. Louis involving allegations that Roundup causes non-Hodgkin’s lymphoma. He also represents clients on appeal and has authored amicus briefs before the United States Supreme Court.

Greg has received numerous accolades for his accomplishments in product liability and mass tort litigation. He has been recognized as a “Rising Star” by Law360 and New York Metro Super Lawyers, and included on Best Lawyers’ “Ones to Watch” list. He was also recognized as an Outstanding Contributor by Lawyers for Civil Justice for his efforts to reform the procedural rules governing mass tort litigation.

Greg joined Covington following a clerkship with the Honorable Paul V. Niemeyer on the United States Court of Appeals for the Fourth Circuit. Prior to his clerkship, Greg graduated magna cum laude from Harvard Law School, where he served as an Executive Editor of the Harvard Law Review.